The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

NCT00747968 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide, a GLP-1 analogue, affects how the heart and brain process glucose in people with type 2 diabetes during high blood sugar levels.

Status Completed The study has finished.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, triple-blind basic-science study

Participants 8 people

Who can join Ages 50–70 · male only

Timeline Started 2010-02 · est. completion 2011-03

Where 4 sites · Denmark

What this study is testing ClinicalTrials.gov NCT00747968 ↗

Description as written by the study sponsor.

30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.

Treatments tested

Byetta, Exenatide also known as placebo Drug

Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once

Main thing measured	steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.
Sponsor	University of Aarhus
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00747968 ↗